Jazz Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $1,045,712 | $897,841 | $1,088,173 | $1,054,969 |
Gross Profit | 929,444 | 793,221 | 959,460 | 943,358 |
EBITDA | -514,182 | 138,861 | 396,981 | 425,442 |
EBIT | -688,191 | -26,012 | 228,564 | 260,210 |
Net Income | -718,470 | -92,541 | 191,115 | 215,055 |
Net Change In Cash | 1,045,712 | 897,841 | 1,088,173 | 1,054,969 |
Free Cash Flow | 100,888 | 390,903 | 385,293 | 387,959 |
Cash | 1,189,880 | 1,861,946 | 2,412,864 | 2,218,135 |
Basic Shares | 61,194 | 60,979 | 61,503 | 63,174 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $4,068,950 | $3,834,204 | $3,659,374 | $3,094,238 |
Gross Profit | 3,623,237 | 3,398,627 | 3,118,857 | 2,653,478 |
EBITDA | 1,521,711 | 1,449,422 | 1,468,615 | 1,027,746 |
EBIT | 861,644 | 810,726 | 839,144 | 475,263 |
Net Income | 560,120 | 414,832 | -224,060 | -328,954 |
Net Change In Cash | 4,068,950 | 3,834,204 | 3,659,374 | 3,094,238 |
Cost of Revenue | 296,256 | -463,114 | ||
Free Cash Flow | 1,347,838 | 1,068,045 | 773,783 | 732,975 |
Cash | 2,412,864 | 1,506,310 | 881,482 | 591,448 |
Basic Shares | 66,007 | 72,066 | 62,539 | 59,694 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$8.25 |
2025-03-31 | -$1.52 |
2024-12-31 | $6.60 |
